a_dose_of_drug_smallbanner_R2

Blog News - A Dose of Drug Development is a web publication produced by Integrium. The blog post content included conveys subjects of discussion and practice in the drug development process along with real-time Integrium activity. Readers interested in following are welcome to comment and interact on the Integrium website blog space.


Integrium, LLC to Attend 2017 Microbiome Drug Development Summit in Boston, MA

Tustin, CA – Integrium Executives will be in Boston for the 2017 Microbiome Drug Development Summit on June 27-29. Intrigued by the summits' information-filled approach, Integrium Executives are looking forward to gaining access to microbiome clinical information to broaden the future in this rapidly changing therapeutic area.

The summit consists of a wide range of topics discussed around microbiome drug development and the future of clinical advancement. Being that the microbiome plays a huge role in our overall health, the need for finding discoveries to help cure diseases is never-ending. The Microbiome Drug Development Summit allows key industry leaders to collaborate with like-minded people and companies that share a common goal and overall advance microbiome medicine.

“Although we have been conducting Microbiome clinical trials for years, we always want to learn more about the microbiome and how to best go about designing safe and effective clinical trials; which gives Integrium the knowledge and understanding to tackle these new, cutting-edge opportunities,” mentioned Mike Loftus, Executive Director of Business Development. Hearing from the clinical side of the microbiome field helps Integrium target their microbiome services to the right companies that are in the market for these unique set of skills.

Integrium Executives are looking forward to being involved in workshops and hearing from speakers that will discuss improving preclinical models for microbiome drug discovery, key factors to designing safe and effective clinical trials, raising investments to advance therapeutic efforts, and more. Having access to the latest information in the microbiome field will provide Integrium with the knowledge to tackle the challenges that exist in the pharmaceutical industry today.

Integrium Executives will be taking meetings throughout the summit and encourage guests to schedule meeting requests with Emily MacHale at Emily.MacHale@integrium.com. We look forward to seeing you there!

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs
and Oncology.

Check out our new website!

www.integrium.com

Contact

To learn more about Integrium, LLC, please contact:

Emily MacHale
Associate Director, Marketing
& Research
Emily.MacHale@integrium.com
908-375-2009


Integrium, LLC to Attend RESI San Diego 2017

By: Emily MacHale

Tustin, CA – Integrium, LLC announced they will be attending RESI San Diego 2017 on June 19, 2017. RESI allows life science companies to connect with investors that come from backgrounds related to Virtual Pharma, Angels, Venture Philanthropy, Patient Groups, Corporate Development, and more. Encouraging in person meetings with pharma companies or service providers and investors, RESI is a place for developing new connections, continuing business relationships, and overall finding capital.

Integrium Executives have always benefited from facilitating meetings during the fast-paced day at RESI. As active members in the life science community, Integrium is able to share the various funding options that are available within their organization, clinical trial expertise in a number of therapeutic areas, and their platform for CRO and investor success.

Integrium is available for meetings throughout the day on Monday, June 19, and welcomes all life science companies, investors, and service providers. To schedule a meeting, please contact Emily MacHale at Emily.MacHale@integrium.com or connect with Mike Loftus, Executive Director of Business Development via the RESI partnering system: http://resi-sd17.meeting-mojo.com/. If the partnering system is unavailable to you, please reach out to Mike directly at mike.loftus@integrium.com

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs
and Oncology.

Check out our new website!

www.integrium.com

Contact

To learn more about Integrium, LLC, please contact:

Emily MacHale
Associate Director, Marketing
& Research
Emily.MacHale@integrium.com
908-375-2009


Integrium, LLC to Attend 2017 BIO International Convention in San Diego, CA

By: Emily MacHale

Tustin, CA – Integrium, LLC announced they will be attending the 2017 BIO International Convention located in San Diego, CA on June 19-22. Integrium is looking forward to joining other industry leaders and pharmaceutical companies to fulfill networking goals and potential partnerships. As with previous years, Integrium will not only be forming relationships, but will be educating themselves on the hot topics in biotechnology, healthcare, and beyond.

BIO is home to numerous networking meetings, companies joining together to find ways to collaborate, and organizations showcasing their objectives and pipeline. With a partnering system that allows attendees to independently register and schedule their own meetings, more than 35,000+ meetings were scheduled for 2016 between 3,500 companies and in only 3.5 days, leading BIO 2017 to be one for the books. Integrium is heavily involved in the partnering system and thoroughly enjoys learning about each company’s goals and initiatives.

Integrium Executives will be taking meetings throughout BIO and encourage guests to schedule meeting requests with Mike Loftus, Executive Director of Business Development and other companies attending BIO via the BIO partnering system http://convention.bio.org/partner/. If you have trouble accessing the link please contact Mike Loftus at Mike.Loftus@integrium.com or Emily MacHale at Emily.MacHale@integrium.com.

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

Check out our new website!

www.integrium.com

To learn more about Integrium, please contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009


Integrium, LLC to Attend 2017 Marcum MicroCap Conference

By: Emily MacHale

Tustin, CA – Integrium, LLC announced they will be attending the 2017 Marcum MicroCap Conference on June 15-16 at the Grand Hyatt New York. Integrium helps micro-cap and small-cap biotechs attain clinical data so they can raise their next round of capital. Many current and prospective clients reach out to Integrium to discuss alternative financing solutions. Integrium executives look forward to meeting with prospective companies in the life science and healthcare sectors, as well as engaging in featured presentations of CEOs and CFOs.

Year after year, the Marcum MicroCap Conference has consistently provided publicly traded companies with less than $500 million in market capitalization the chance to network with the investment community. The conference consists of a full itinerary of expert panels on important topics related to the investment field. The event draws fund managers and high net worth investors who concentrate on small-cap equities.

Some of the industries that presenting companies are involved in are Life Sciences and Healthcare, Financial and Asset Management Services, Software and Business Services, and Retail and Consumer Products. The 2017 key note speakers for the conference are involved in various industries such as politics, economics, and finance.

About Integrium

Through a trusted partnership with PoC Capital, Integrium is able to assist micro- cap, small-cap, and privately held biotechs looking to raise additional financing, by providing new clinical data to create the next bump in valuation. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases.

Check out our new website!

www.integrium.com

Contact

To learn more about Integrium, contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009


Integrium, LLC to Attend Alliance for Regenerative Medicine 5th Annual Cell & Gene Investor Day in Boston!

By: Emily MacHale

Tustin, CA – Executives of the Integrium team will be in Boston during the Alliance for Regenerative Medicine 5th Annual Cell & Gene Investor Day on April 27th, 2017. On this one day filled with opportunity for investors to collaborate with advanced therapeutic biotechs, Integrium seeks to meet and gain insight on how they can be of help to numerous life science experts.

Hearing from industry leaders helps Integrium with effectively positioning themselves in the biotech marketplace regarding investment and financing opportunities. Meanwhile, Integrium can understand the needs of biotechs and what they require during their search for an investor. With over 350 attendees and more than 175 of them active investors and analysts, Integrium is successfully able to meet with clinical experts and develop one-on-one relationships.

Integrium helps micro-cap, small-cap, and small private biotechs attain clinical data so they can raise their next round of capital. Integrium typically invests in two to four private biotechs each year and have the ability and goal to take on 3 more investments in 2017. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

Check out our new website!

www.integrium.com

To learn more about Integrium, contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009


Get a second opinion for your RFP or budget

Should my biotech get a second opinion?

Have you had the same family doctor, the same dentist, and the same eye doctor…. for your entire life?

What if someone told you that there are thousands upon thousands of other doctors out there that could give you more feedback, alternative options or even lower pricing?

As a Clinical CRO partner to many, Integrium wants biotechnology Executives and Managers to choose Integrium as THE second opinion for your RFP and/or budget.

The plus side to a small CRO

Branching outside of the usual large CRO suspects and coming to Integrium can open up numerous doors of flexibility with pricing, personal one-on-one relationships, open communication, and direct-line access to key clinical and business executives.

Within our niche areas of expertise, Integrium strives to be the top CRO with services and offerings like none other. Relationship focused and privately owned, we have the opportunity for price flexibility, financing options for micro-caps with open shelf registration, full service CRO offerings, a la carte clinical services, and beyond.

“It is better to be a bigfish in a small pond than a small fish in a mighty ocean”

Many times, small biotechs have more difficulty working with large CROs than a small biotech has working with a properly-sized CRO. Being on the same playing field tends to have better advantages when it comes to communication, financial concerns, and common goals.

No matter what size biotech you are, set yourself up for success by coming to Integrium for a second opinion on your RFP and/or budget to see how we can make a difference, together, in your world today.